

Robert F Kelley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10114655/publications.pdf>

Version: 2024-02-01

36
papers

2,829
citations

279798

23
h-index

361022

35
g-index

36
all docs

36
docs citations

36
times ranked

3027
citing authors

#	ARTICLE	IF	CITATIONS
1	Generation of a Porcine Antibody Fab Fragment Using Protein Engineering to Facilitate the Evaluation of Ocular Sustained Delivery Technology. <i>Molecular Pharmaceutics</i> , 2022, , .	4.6	0
2	Identification and characterization of an octameric PEG-protein conjugate system for intravitreal long-acting delivery to the back of the eye. <i>PLoS ONE</i> , 2019, 14, e0218613.	2.5	20
3	Influence of Charge, Hydrophobicity, and Size on Vitreous Pharmacokinetics of Large Molecules. <i>Translational Vision Science and Technology</i> , 2019, 8, 1.	2.2	38
4	Protein conjugates and fusion proteins as ocular therapeutics. <i>Drug Discovery Today</i> , 2019, 24, 1440-1445.	6.4	8
5	In Vivo Stability Profiles of Anti-factor D Molecules Support Long-Acting Delivery Approaches. <i>Molecular Pharmaceutics</i> , 2019, 16, 86-95.	4.6	6
6	Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates. <i>MAbs</i> , 2017, 9, 756-766.	5.2	33
7	Protein engineering to increase the potential of a therapeutic antibody Fab for long-acting delivery to the eye. <i>MAbs</i> , 2017, 9, 1297-1305.	5.2	16
8	Contribution of Antibody Hydrodynamic Size to Vitreal Clearance Revealed through Rabbit Studies Using a Species-Matched Fab. <i>Molecular Pharmaceutics</i> , 2016, 13, 2996-3003.	4.6	62
9	Enhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 5679-5684.	7.1	73
10	Evaluating the Use of Antibody Variable Region (Fv) Charge as a Risk Assessment Tool for Predicting Typical Cynomolgus Monkey Pharmacokinetics. <i>Journal of Biological Chemistry</i> , 2015, 290, 29732-29741.	3.4	67
11	Molecular Assessment of Monoclonal Antibody-Based Therapeutics Enabling Lead Selection for Clinical Development. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2015, , 153-180.	0.6	4
12	Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge. <i>MAbs</i> , 2014, 6, 1255-1264.	5.2	104
13	In silico selection of therapeutic antibodies for development: Viscosity, clearance, and chemical stability. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 18601-18606.	7.1	190
14	In vitro affinity maturation of a natural human antibody overcomes a barrier to in vivo affinity maturation. <i>MAbs</i> , 2014, 6, 437-445.	5.2	23
15	Structural Basis of Signaling Blockade by Anti-IL-13 Antibody Lebrikizumab. <i>Journal of Molecular Biology</i> , 2013, 425, 1330-1339.	4.2	133
16	Glycan Shifting on Hepatitis C Virus (HCV) E2 Glycoprotein Is a Mechanism for Escape from Broadly Neutralizing Antibodies. <i>Journal of Molecular Biology</i> , 2013, 425, 1899-1914.	4.2	105
17	Effects of altered Fc γ 3R binding on antibody pharmacokinetics in cynomolgus monkeys. <i>MAbs</i> , 2013, 5, 896-903.	5.2	90
18	Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity. <i>MAbs</i> , 2013, 5, 872-881.	5.2	67

#	ARTICLE	IF	CITATIONS
19	A strategy for risk mitigation of antibodies with fast clearance. <i>MAbs</i> , 2012, 4, 753-760.	5.2	200
20	Inhibiting Alternative Pathway Complement Activation by Targeting the Factor D Exosite. <i>Journal of Biological Chemistry</i> , 2012, 287, 12886-12892.	3.4	75
21	Methods to Engineer and Identify IgG1 Variants with Improved FcRn Binding or Effector Function. <i>Methods in Molecular Biology</i> , 2012, 901, 277-293.	0.9	12
22	Receptor-selective Mutants of Apoptosis-inducing Ligand 2/Tumor Necrosis Factor-related Apoptosis-inducing Ligand Reveal a Greater Contribution of Death Receptor (DR) 5 than DR4 to Apoptosis Signaling. <i>Journal of Biological Chemistry</i> , 2005, 280, 2205-2212.	3.4	237
23	Similar Molecular Interactions of Factor VII and Factor VIIa with the Tissue Factor Region that Allosterically Regulates Enzyme Activity. <i>Biochemistry</i> , 2004, 43, 1223-1229.	2.5	17
24	The 1.85 Å... resolution crystal structures of tissue factor in complex with humanized fab d3h44 and of free humanized fab d3h44: revisiting the solvation of antigen combining sites 1 Edited by I. Wilson. <i>Journal of Molecular Biology</i> , 2001, 313, 83-97.	4.2	36
25	The Tissue Factor Region That Interacts with Factor Xa in the Activation of Factor VII. <i>Biochemistry</i> , 2001, 40, 675-682.	2.5	49
26	The Tissue Factor Region That Interacts with Substrates Factor IX and Factor X. <i>Biochemistry</i> , 2000, 39, 7380-7387.	2.5	68
27	A Unique Zinc-Binding Site Revealed by a High-Resolution X-ray Structure of Homotrimeric Apo2L/TRAIL. <i>Biochemistry</i> , 2000, 39, 633-640.	2.5	262
28	Antibody variable region binding by <i>Staphylococcal</i> protein A: Thermodynamic analysis and location of the Fv binding site on E α domain. <i>Protein Science</i> , 1999, 8, 1423-1431.	7.6	86
29	Triggering Cell Death. <i>Molecular Cell</i> , 1999, 4, 563-571.	9.7	412
30	Hinge bending within the cytokine receptor superfamily revealed by the 2.4 Å... crystal structure of the extracellular domain of rabbit tissue factor. <i>Protein Science</i> , 1998, 7, 1106-1115.	7.6	19
31	A Novel Soluble Tissue Factor Variant with an Altered Factor VIIa Binding Interface. <i>Journal of Biological Chemistry</i> , 1998, 273, 4149-4154.	3.4	8
32	Potent Bifunctional Anticoagulants: Kunitz Domain-Tissue Factor Fusion Proteins. <i>Biochemistry</i> , 1997, 36, 5607-5611.	2.5	20
33	A Soluble Tissue Factor Mutant Is a Selective Anticoagulant and Antithrombotic Agent. <i>Blood</i> , 1997, 89, 3219-3227.	1.4	67
34	Analysis of the Factor VIIa Binding Site on Human Tissue Factor: Effects of Tissue Factor Mutations on the Kinetics and Thermodynamics of Binding. <i>Biochemistry</i> , 1995, 34, 10383-10392.	2.5	102
35	Antigen binding thermodynamics and antiproliferative effects of chimeric and humanized anti-p185HER2 antibody Fab fragments. <i>Biochemistry</i> , 1992, 31, 5434-5441.	2.5	103
36	Thermodynamics of ligand binding and denaturation for his64 mutants of tissue plasminogen activator kringle-2 domain. <i>Proteins: Structure, Function and Bioinformatics</i> , 1991, 11, 35-44.	2.6	17